NASDAQ:RAPP Rapport Therapeutics Q2 2026 Earnings Report $49.33 +1.09 (+2.26%) Closing price 04:00 PM EasternExtended Trading$49.30 -0.02 (-0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Rapport Therapeutics EPS ResultsActual EPS-$1.19Consensus EPS -$1.12Beat/MissMissed by -$0.07One Year Ago EPSN/ARapport Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$2.22 millionBeat/MissN/AYoY Revenue GrowthN/ARapport Therapeutics Announcement DetailsQuarterQ2 2026Date8/5/2026TimeBefore Market OpensConference Call DateWednesday, August 5, 2026Conference Call Time7:00AM ETUpcoming EarningsRapport Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Rapport Therapeutics Earnings HeadlinesRapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical ProgramAugust 24 at 7:00 AM | globenewswire.comRapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy FranchiseAugust 21 at 6:29 PM | seekingalpha.comThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick. The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names. Chaikin lays out the full case in a new free presentation, no email or credit card required.August 24 at 1:00 AM | Chaikin Analytics (Ad)BTIG Research Reaffirms Buy Rating for Rapport Therapeutics (NASDAQ:RAPP)August 21 at 1:24 AM | americanbankingnews.comBrokers Issue Forecasts for RAPP Q1 EarningsAugust 16, 2026 | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Expected to Rise, HC Wainwright Analyst SaysAugust 14, 2026 | americanbankingnews.comSee More Rapport Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rapport Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapport Therapeutics and other key companies, straight to your email. Email Address About Rapport TherapeuticsRapport Therapeutics (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology. Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation. Its diverse pipeline includes antibody-based constructs and small-molecule inhibitors targeting both solid tumors and hematologic malignancies. Preclinical data have demonstrated promising anti-tumor activity and favorable safety profiles, supporting the advancement of several programs toward first-in-human studies. Headquartered in Massachusetts, Rapport Therapeutics collaborates with academic institutions, contract research organizations and industry partners to drive its research and development efforts. The company is led by a management team with extensive experience in oncology drug development, clinical operations and regulatory strategy. With a strategic focus on translating scientific insights into innovative cancer therapies, Rapport aims to improve outcomes for patients worldwide. View Rapport Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It MattersMongoDB Is Surging—And the Next Catalyst Is Almost Here5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here's WhyMarketBeat Week in Review – 08/17 - 08/21BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish SetupFlash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to Watch$27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Upcoming Earnings Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
